NPNima Parvaneh

Nima Parvaneh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nima Parvaneh has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biallelic loss-of-function PTPN6 variants lead to inflammatory lung disease and hemolytic anemia

    by S. Farshid Moussavi-Harami, Matt S. Zinter, Marialetizia Motta, Luca Pannone, Paolo Calligari, Luca Mignini, Anne Slavotinek, Pierre-Marie Martin, Henry Sanchez, Lauren Sanchez, et al.

    Severe inflammatory lung disease, including acute respiratory distress syndrome (ARDS), is life-threatening with diverse causes and few targeted therapies. Inborn errors of immunity (IEIs) underlie a subset of cases. We describe a novel IEI caused by biallelic loss-of-function variants in PTPN6, encoding the immunoregulatory phosphatase SHP1. Seven children from five families developed early-onset anemia and severe inflammatory lung disease, at times presenting as ARDS. The causative variants were shown to destabilize SHP1 and abolish its phosphatase activity. These findings expand the genetic landscape of inflammatory lung disease and suggest SHP1 activation as a potential therapeutic strategy for immune-mediated pulmonary pathology.

  • Open Access

    ER proteostasis failure in HYOU1 deficiency alters B cells, neutrophils, and interferon signalling

    by Aida Idani, Sabrina Bibi-Triki, Tristan Stemmelen, Mirjana Radosavljevic, Pierre Grenot, Aurélie Hirschler, Alice Bernard, Michelle Rosenzwajg, Jianying Yang, Alice Eischen, et al.

    Hypoxia upregulated 1 (HYOU1) is a stress-inducible ER chaperone. We investigated 2 unrelated patients carrying biallelic HYOU1 variants and presenting with primary immunodeficiency. Patient 1, homozygous for p.Pro444His, displayed failure to thrive, hypoglycemia, B cell lymphopenia, and neutropenia. Patient 2, compound heterozygous for p.Arg262Gln and p.Pro757_Glu758insAla, exhibited recurrent infections, enteropathy, and hypogammaglobulinemia. In Patient 1, while HYOU1 transcription was preserved, the protein was severely reduced. Tunicamycin treatment of dermal fibroblasts showed a blunted unfolded protein response and defective induction of ER stress–responsive genes. Immunophenotyping showed near-absence of circulating B cells, and single-cell RNA sequencing of bone marrow identified an arrest at the pro-B cell stage. Neutrophils displayed hypogranulation and dysregulated IFN- and apoptosis-associated transcriptional signatures, unresponsive to G-CSF. HYOU1 deficiency hence results in ER stress–induced proteostasis failure that simultaneously impairs adaptive immunity through B cell developmental arrest and innate immunity through neutrophil dysfunction and IFN pathway imbalance. This work expands the spectrum of HYOU1 deficiency and further identifies ER proteostasis as a central determinant of immune homeostasis.

  • Open Access

    Progressive multifocal leukoencephalopathy in a 15-year-old boy with X-linked hyper-IgM syndrome: a case report

    by Saeedeh Delavari, Ali Pourvali, Mehran Akbari, Shiva Vajdian, Nima Parvaneh, Behzad Khansarinejad, Hossein Yousefimanesh, Morteza Heidari, Atbin Latifi Kasani, Seyed Amir Hossein Mirmoeini, et al.

  • Familial pulmonary alveolar proteinosis and type I interferonopathy by mutation of STAT2 (TIMS2)

    by Conor Gruber, Meredith Ramba, Bineeta Debnath, Lorenzo Cuollo, Anna-Lena Neehus, Angelica Lee, Sofija Buta, Marta Martin-Fernandez, Jérémie Rosain, Laureline Berteloot, et al.

    Mutations that enhance type I interferon (IFN-I) activity cause monogenic autoinflammatory disorders termed type I interferonopathies. Along with the typical neurologic and rheumatologic manifestations, severe pulmonary disease is increasingly recognized yet poorly understood. We studied three siblings presenting with early-onset, life-threatening pulmonary alveolar proteinosis (PAP) and autoinflammatory stigmata. Genetic analysis uncovered a novel homozygous variant (R223Q) in STAT2, a key mediator of IFN-I signaling, which also facilitates feedback inhibition via USP18. R223Q STAT2 preserved signal transduction and viral control in vitro. However, cells homozygous for the R223Q variant failed to terminate IFN-I responses, owing to impaired localization of USP18. Unlike in classical forms of PAP, GM-CSF signaling remained intact. Instead, persistent IFN-I signaling antagonized monocyte migration toward chemokines essential for lung trafficking. Informed by these findings, the youngest sibling received JAK inhibitor and anti-IFN-I receptor therapy with marked clinical improvement. Collectively, type I interferonopathy by mutation of STAT2 (TIMS2) compromises monocyte chemotaxis and underlies a novel mechanism of PAP.


  • Open Access

    Humans homozygous for rare or common hypomorphic IL23R variants are prone to tuberculosis

    by Diana Olguín Calderón, Laura E. Kilpatrick, Clément Conil, Quentin Philippot, Masato Ogishi, Joseph Vellutini, Ji Eun Han, Narelle Keating, Hailun Li, Geetha Rao, et al.

    Homozygosity for rare loss-of-function IL23R variants abolishes IL-23–dependent IFN-γ production by lymphocytes, including NK and innate-like T cells, thereby underlying clinical disease due to weakly virulent mycobacterial species. We report selective enrichment in homozygosity for four hypomorphic IL23R variants in our cohort of patients with tuberculosis. Three of these IL23R alleles are rare (G300V, G149R, and L372F), with a minor allele frequency (MAF) under 1%, but the fourth (R381Q) is surprisingly common, with an MAF as high as 10.2% in certain populations. The other 15 missense alleles found in the homozygous state in public databases are isomorphic. The four hypomorphic IL-23R variants identified dimerize with IL-12Rβ1 and bind IL-23. However, their function is impaired by low levels of cell surface expression (R381Q, G300V) and/or as a consequence of conformational changes altering agonist efficacy. IFN-γ production in response to IL-23 is impaired in innate-like T cells and NK cells. These data suggest that recessive partial IL-23R deficiency, whether due to rare or common variants, confers a predisposition to tuberculosis while preserving immunity to less virulent mycobacteria.


  • Open Access

    RASGRP1 Deficiency Manifesting as Severe Vasculopathy and Fatal Autoimmune Hemolytic Anemia

    by Kosar Asna Ashari, Bahareh Yaghmaie, Neda Pak, Mohammad Shahrooei, Vahid Ziaee, Nima Parvaneh

    Background: RASGRP1 deficiency is a rare inborn error of immunity characterized by immunodeficiency, autoimmunity, and lymphoproliferation. Results: We report a 5‐year‐old male with novel homozygous splice‐donor mutations in RASGRP1 (c.1720+1G>A and c.1720+2T>C) who presented with severe vasculopathy (ischemic stroke and thrombosis), secondary antiphospholipid syndrome, and fatal refractory autoimmune hemolytic anemia. Conclusion: A review of 14 previously reported cases (plus current case) confirms that while infections (100%) and lymphoproliferation (87%) are common, vascular autoimmunity is an emerging life‐threatening phenotype. Hematopoietic stem cell transplantation remains the only curative therapy, as conservative management carries high mortality. Early genetic diagnosis is essential for optimal management. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission

  • Open Access

    STAT2 R148 variant: A 16th-century founder mutation and clinical response to high-dose JAK inhibitor therapy

    by Nima Parvaneh, Rasol Molatefi, Conor Gruber, Sajjad Biglari, Leila Moradi, Yoann Seeleuthner, Fatima Ailal, Ahmed Aziz Bousfiha, Neda Pak, Camille Soudée, et al.

    Patients with STAT2 p.R148Q variant present with life-threatening neuroinflammation, respiratory failure, and high mortality rate. Early genetic recognition and treatment with high-dose JAK inhibitors may improve outcomes in this devastating but potentially treatable interferonopathy.

  • Open Access

    Human LFA-1 governs T cell immune surveillance of the skin

    by Ahmad Yatim, Leila Youssefian, Aida Idani, Haralambos Mourelatos, Nasrin Alipour Olyaei, Laleh Habibi, Jessica N. Peel, Maira Gaballa, Colin Kim, Danyel Lee, et al.

    The human integrin lymphocyte function–associated antigen 1 (LFA-1; αLβ2) is broadly expressed on leukocytes and involved in various intercellular adhesions. We report complete LFA-1 deficiency because of inherited αL (CD11a) deficiency in otherwise healthy adults of various ancestries with skin lesions due to commensal papillomaviruses. The patients had no history of invasive infections characteristic of children with inherited deficiency of β2 (CD18), which forms heterodimers with αL, αM (CD11b), αX (CD11c), or αD (CD11d). The development and function of leukocyte subsets are largely preserved in the absence of LFA-1. However, the transendothelial migration of skin-tropic cutaneous lymphocyte antigen (CLA) + memory T cells is severely impaired, resulting in their selective sequestration in the blood. Conversely, alternative integrins mediate the extravasation of other leukocytes, including other T cell subsets, to other tissues. Human LFA-1 is required for steady-state T cell homing to the skin and control of papillomaviruses but is otherwise largely redundant. Integrin-mediated T cell compartmentalization is thus essential for organ-selective immune surveillance.


  • Top Cited Papers
    Open Access

    TLR7 F507S gain-of-function mutation presenting with early-onset SLE and hypertriglyceridemia: Response to JAK inhibition

    by Nima Parvaneh, Hossein Karami, Leila Shahbaznejad, Zahra Rezaei, Parastoo Rostami, Mohammad Shahrooei, Vahid Ziaee

    We present a patient harboring the TLR7 F507S mutation who initially presented with refractory thrombocytopenia that evolved into SLE with subtle neurologic features, accompanied by hypertriglyceridemia. Both hematological and metabolic features responded to ruxolitinib, thereby expanding the phenotypic spectrum and therapeutic understanding of TLR7 GOF disease.


  • Open Access

    Genotypes truncating the intracellular tail of human pre-TCRα: From amorphic to isomorphic

    by Marie Materna, Christian Beetz, Christian A. Ganoza, Caroline Deswarte, Lucien Pereira Estrela, Nima Parvaneh, Jean-Laurent Casanova, Vivien Béziat

    Using large genomic datasets, we identified six individuals homozygous for intracellular tail truncating PTCRA variants. Functional assays revealed two hypomorphic and one neutral alleles, demonstrating that most intracellular truncations retain pre-TCRα activity, establishing the tail as largely dispensable for pre-TCR assembly.